• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

34.81 -0.48 (-1.36%)
Streaming Delayed Price Updated: 12:28 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,193,532
Open 35.21
Bid (Size) 34.80 (300)
Ask (Size) 34.82 (200)
Prev. Close 35.29
Today's Range 34.23 - 35.33
52wk Range 14.99 - 37.34
Shares Outstanding 1,110,352,397
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
Today 7:00 EDT
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗
July 06, 2026
Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion. 
Via The Motley Fool

Performance

YTD
+12.5%
+12.5%
1 Month
+4.7%
+4.7%
3 Month
+16.7%
+16.7%
6 Month
+12.3%
+12.3%
1 Year
+106.6%
+106.6%

More News

Read More
News headline image
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain? ↗
June 19, 2026
Via The Motley Fool
News headline image
Teva Releases Q2 2026 Aide Memoire
June 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) Flags Technical Breakout Setup with Top Ratings ↗
May 30, 2026
Via Chartmill
News headline image
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
June 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
June 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock? ↗
June 12, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
June 10, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
June 08, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
June 08, 2026
From Alvotech
Via GlobeNewswire
News headline image
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
June 05, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®
June 04, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
June 04, 2026
From Alvotech
Via GlobeNewswire
News headline image
Teva to Present at the Goldman Sachs Global Healthcare Conference
June 01, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks ↗
June 01, 2026
Via The Motley Fool
News headline image
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
May 21, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
May 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
May 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More. ↗
May 15, 2026
Via The Motley Fool
News headline image
Wall Street Thinks Teva Stock Still Has Room to Run After Soaring Over 100%. Here's Why Analysts Are Right. ↗
May 14, 2026
Via The Motley Fool
News headline image
Teva to Present at the BofA Securities Health Care Conference
May 04, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
April 30, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't? ↗
April 30, 2026
Via The Motley Fool
News headline image
Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
April 29, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire

Frequently Asked Questions

Is Teva Pharmaceutical Industries Limited American Depositary Shares publicly traded?
Yes, Teva Pharmaceutical Industries Limited American Depositary Shares is publicly traded.
What exchange does Teva Pharmaceutical Industries Limited American Depositary Shares trade on?
Teva Pharmaceutical Industries Limited American Depositary Shares trades on the New York Stock Exchange
What is the ticker symbol for Teva Pharmaceutical Industries Limited American Depositary Shares?
The ticker symbol for Teva Pharmaceutical Industries Limited American Depositary Shares is TEVA on the New York Stock Exchange
What is the current price of Teva Pharmaceutical Industries Limited American Depositary Shares?
The current price of Teva Pharmaceutical Industries Limited American Depositary Shares is 34.81
When was Teva Pharmaceutical Industries Limited American Depositary Shares last traded?
The last trade of Teva Pharmaceutical Industries Limited American Depositary Shares was at 07/07/26 12:28 PM ET
What is the market capitalization of Teva Pharmaceutical Industries Limited American Depositary Shares?
The market capitalization of Teva Pharmaceutical Industries Limited American Depositary Shares is 38.65B
How many shares of Teva Pharmaceutical Industries Limited American Depositary Shares are outstanding?
Teva Pharmaceutical Industries Limited American Depositary Shares has 39B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap